Background: The frequency of functional bowel disorders (FBD) in Mexico using the Rome II criteria is unknown. Methods: The Rome II Modular Questionnaire (RII-MQ) was translated into Spanish in coordination with the Rome Committee and their Latin American program. Volunteers were recruited by advertisement in Mexico City, and administered the RII-MQ. Results:The study population consisted of 324 healthy volunteers, with a mean age of 35.7; 66% were female. The most prevalent disorders were heartburn 35%, irritable bowel syndrome (IBS) 35%, functional bloating 21%, proctalgia fugax 21%, and functional constipation 19%. Based on gender, IBS-C was 4 times more frequent in females than males (19 vs. 4.6%) and functional bloating 3 times more frequent (10 vs. 3.7%). Differences according to occupation included a higher prevalence of ulcer-like dyspepsia (p = 0.04), IBS-C (p = 0.018) and proctalgia fugax (p = 0.034) among students. Conclusions: This is the first study to use RII-MQ to determine the prevalence of FBD in urban Mexico. The prevalence of IBS was significant and is related to a number of factors, including the stress of living in an overpopulated city. Selection bias is likely operative. A community-based study is warranted.
© 2006 S. Karger AG, Basel
- Functional bowel disorders, frequency
- Functional bowel disorders, Mexico
- Functional bowel disorders, Rome II criteria
- Rome II Modular Questionnaire
- Irritable bowel syndrome
- Huerta I, Valdovinos MA, Schmulson M: Irritable bowel syndrome in Mexico. Dig Dis 2001;19:251–257.
- Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43–II47.
- Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, The Rome II Multinational Working Teams: The Functional Gastrointestinal Disorders, ed 2. McLean/VA, Degnon Associates, 2000.
- Sperber A, DeVellis RF, Boehlecke B: Cross-cultural translation. Methodology and validation. J Cross Cult Psychol 1994;25:5001.
- Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–1456.
- Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F: Symptoms of gastroesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004;19:95–105.
- Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: a technical review for practice guidelines development. Gastroenterology 1997;112:2120–2137.
- Kang JY: Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther 2005;21:663–676.
- Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L: Functional gastrointestinal disorders in Canada. First population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002;47:225–235.
- Lu CL, Chen CY, Lang HC, Luo JC, Wang SS, Chang FY, Lee SD: Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther 2003;18:1159–1169.
- Kwan ACP, Bao TN, Chakkaphak S, Chang FY, Ke MY, Law NM, Leelakusolvong S, Luo JY, Manan C, Park HJ, Piyaniran W, Qureshi A, Long T, Xu GM, Xu L, Yuen H: Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 2003;18:796–802.
- Gwee KA, Wee S, Wong ML, Png DJ: The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol 2004;99:924–931.
- Celebi S, Acik Y, Deveci SE, Bahcecioglu IH, Ayar A, Demir A, Durukan P: Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004;19:738–743.
- Saito YA, Talley NJ, Melton J, Fett S, Zinsmeister AR, Locke GR: The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003;15:687–694.
- Talley NJ, Boyce P, Jones M: Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998;42:690–695.
- Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B: Gender-related differences in IBS symptoms. Am J Gastroenterol 2001;96:2184–2193.
- Simren M, Abrahamsson H, Svedlund J, Bjornsson ES: Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol 2001;36:545–552.
- Talley NJ: Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S3–S10.
- Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al: US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993;38:1569–1580.
- Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E, Lipton RB, Farup CE: Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999;94:3530–3540.
- Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L: An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130–3137.
- Ortiz O, Schmulson M: Calidad de Vida de los pacientes con estreñimiento crónico de acuerdo al tránsito colonico con marcadores radioopacos. Servicio Social en Investigación, Secretaría de Salud, México 2005.
- Whitehead WE, Wald A, Diamant NE, Enck P, Pemberton JH, Rao SS: Functional disorders of the anus and rectum. Gut 1999;45(suppl II):II55–II59.
- Wald A: Functional anorectal and pelvic pain. Gastroenterol Clin North Am 2001;30:243–251.
Dr. Max Schmulson
Departamento de Medicina Experimental, Facultad de Medicina
Universidad Nacional Autónoma de México (UNAM), Hospital General de México
Doctor Balmis #148, Col. Doctores, CP 06726, Del. Cuahutemoc, México DF (Mexico)
Tel. +52 5556 232 673, Fax +52 5556 232 669, E-Mail email@example.com
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 2, Number of References : 24
Digestive Diseases (Clinical Reviews)
Vol. 24, No. 3-4, Year 2006 (Cover Date: July 2006)
Journal Editor: Malfertheiner, P. (Magdeburg)
ISSN: 0257–2753 (print), 1421–9875 (Online)
For additional information: http://www.karger.com/DDI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.